CCO Infectious Disease Podcast
Christine Katlama and Babafemi Taiwo: Answering the Questions on Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced People With HIV
Episode Summary
Hear from expert faculty as they discuss questions regarding the management of people with HIV who are heavily treatment experienced or experiencing treatment failure.
Episode Notes
In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:
- Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimens
- Maintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABC
- ART regimen simplification
- When to perform genotypic resistance testing, including for PWH who have been off ART
- When to perform DNA genotyping for archived resistance testing
- Considering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ART
- Using boosted DRV + DTG in salvage regimens
- Switching from boosted PIs to INSTIs in PWH receiving second-line therapy
- Second-line regimens with LA CAB + RPV failure
Christine Katlama, MD
Professor
Sorbonne University APHP Paris
Head, HIV/Hepatitis Clinical and Research Unit
Department of Infectious Diseases
Paris, France
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Link to full program: https://bit.ly/3Z44Gq3